Form 4: Precision BioSciences Director Samuel C. Wadsworth Reports Acquisition of Restricted Stock Units

Director Samuel C. Wadsworth acquired 9,826 Restricted Stock Units (RSUs) of Precision BioSciences on June 4, 2024, according to a Form 4 filing.

Summary

• On June 4, 2024, Samuel C. Wadsworth, a director of Precision BioSciences Inc. (DTIL), acquired 9,826 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Precision BioSciences' Common Stock or an equivalent cash amount.
• The RSUs vest on the earlier of June 4, 2025, or the day before the next annual meeting of stockholders, contingent upon continued service to the Issuer.
• The transaction was reported on June 6, 2024, via a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock units acquisition by a director, indicating alignment with the company's performance but not necessarily a strong positive or negative signal.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon continued service, aligning the director's interests with the company's long-term performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in the company's securities. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's valuation and prospects.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's confidence in the company.

Key Dates